Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Browsing publications by Dr Nicola Cresti

Newcastle AuthorsTitleYearFull text
Dr Sam Orange
Dr Nicola Cresti
Effect of exercise before and/or during taxane-containing chemotherapy treatment on chemotherapy-induced peripheral neuropathy symptoms in women with breast cancer: systematic review and meta-analysis2025
Dr Nicola Cresti
Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom2024
Dr Ruth Norris
Dr Rosie Dew
Professor Alastair Greystoke
Dr Nicola Cresti
Henry Cain
et al.		Sociodemographic Disparities in HER2+ Breast Cancer Trastuzumab Receipt: An English Population-Based Study2024
Dr Jingky Lozano-Kuehne
Dr Nicola Cresti
Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)2023
Dr David Jamieson
Dr Nicola Sunter
Sara Muro
Dr Nicola Cresti
Julieann Sludden
et al.		Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide2017
Dr David Jamieson
Melanie Griffin
Julieann Sludden
Dr Yvette Drew
Dr Nicola Cresti
et al.		A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours2016
Dr Despoina Televantou
Dr Nicola Cresti
Calpain-1 is associated with adverse relapse free survival in breast cancer: a confirmatory study2016
Dr Nicola Cresti
Dr Despina Televantou
Dr David Jamieson
Dr Mark Verrill
Professor Alan Boddy
Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cance2016
Dr Nicola Cresti
Dr Linda Hogarth
Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.2015